Show results for
Refine by
Solid Tumor Suppliers Serving Jordan
54 companies found
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also ...
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
Kailos Iota combines TargetRich, our foundational genetic enrichment technology, with next-generation sequencing and statistical machine learning that results in a highly specific cancer assay of multiple solid ...
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through ...
based inSaint Louis, MISSOURI (USA)
Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...
Sequoia is developing an anticancer compound (SQ1274) for use against solid tumors including ovarian and lung ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
Whole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to ...
based inShanghai, CHINA
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 ...
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United ...
based inSalt Lake City, UTAH (USA)
PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established global distribution. PYREXAR Hyperthermia treatments increase the ...
Deep Regional system using an annular phased array configuration to shape and focus thermal energy on targeted treatment using Sigma Eye Wave ...
based inBergisch Gladbach, GERMANY
For more than 30 years, Miltenyi Biotec has played an important role in the design, development, manufacture, and integration of products that empower the advancement of biomedical research and enable cell and gene therapy. Our expertise spans ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...